2024-05-06 03:26:12 ET
Summary
- DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results.
- Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch as a primary display for blood sugars.
- Despite concerns over timing and other risks, I believe there will be sustained revenue growth and that there is potential for long-term price accretion.
Editor's note: Seeking Alpha is proud to welcome Nicholas Sylvia as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » ...
Read the full article on Seeking Alpha
For further details see:
DexCom: Attractive Discount After Strong Earnings Results